Clinical trials: MAB
Follicular Lymphoma, Non-Hodgkin's Lymphoma
Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma
Background: The disease follicular lymphoma (FL) develops when the body makes abnormal B-cells. These cells usually build up in the lymph nodes, but can also affect other parts of the body.
- Conditions
- Follicular Lymphoma, Non-Hodgkin's Lymphoma, NHL
- Trial name
- NCT03789240
- Testing
- Rituximab, Copanlisib, Bone Marrow Aspiration/Biopsy
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- National Cancer Institute (NCI)
Type 1 Diabetes Mellitus
Safety, Tolerability and Efficacy of Immunomodulation With AT-1501 in Islet Cell Transplantation
This study will evaluate the safety, tolerability and efficacy of AT-1501 in an immunomodulation regimen in adult patients with T1D undergoing an islet cell transplant.
- Trial name
- NCT04711226
- Testing
- AT-1501
- Where
- Canada
- Sponsor
- Anelixis Therapeutics, LLC
Advanced Solid Tumors, Metastatic Solid Tumors
NP137 Clinical and Biological Activities Assessment in Patients With Advanced/Metastatic Solid Tumors Treated by Standard Anti PD-1/PD-L1 Immunotherapies
This study is a multicenter, open-label, proof-of-concept study aiming to assess the clinical and biological impact of NP137 when added to standard PD-1/PD-L1 blockade therapy in 3 independent cohorts of advanced or metastatic…
- Trial name
- IMMUNONET (NCT05605496)
- Testing
- NP137, anti-PD-1/PD-L1
- Where
- 5 sites in France
- Volunteers
- 57 people
- Sponsor
- Centre Leon Berard
Prostate Cancer
A Study of Olaratumab (IMC-3G3) in Prostate Cancer
This is a study evaluating the safety and efficacy of the monoclonal antibody olaratumab plus mitoxantrone plus prednisone compared to mitoxantrone plus prednisone in metastatic castration-refractory prostate cancer following…
- Trial name
- NCT01204710
- Testing
- Olaratumab, Mitoxantrone, Prednisone
- Where
- 40 sites in Belgium, Czechia and 5 more
- Volunteers
- 123 people
- Sponsor
- Eli Lilly and Company
Unspecified Adult Solid Tumor, Protocol Specific
Monoclonal Antibody Plus Cyclophosphamide in Treating Patients With Metastatic Cancer
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00002482
- Testing
- antibody therapy, biological therapy, muromonab-CD3
- Where
- United States
- Sponsor
- St. Vincent Medical Center - Los Angeles
Breast Cancer
Radiolabeled Monoclonal Antibody Followed by Peripheral Stem Cell Transplantation in Treating Patients With Relapsed or Metastatic Breast Cancer
RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00020410
- Testing
- filgrastim, peripheral blood stem cell transplantation, yttrium Y 90 monoclonal antibody B3
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Neoplasms, Ovarian Neoplasms
Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer
This is a two-part, Phase 1, open-label, multicenter, dose escalation study of KHK2866 as monotherapy in patients with advanced solid tumors, and in combination with chemotherapy in subjects platinum-sensitive and…
- Conditions
- Neoplasms, Ovarian Neoplasms, Fallopian Tube Neoplasms, Primary Peritoneal Neoplasm
- Trial name
- NCT01279291
- Testing
- KHK2866, Gemcitabine and Carboplatin, paclitaxel
- Where
- 7 sites in United States
- Volunteers
- 22 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Malaria
L9LS MAb in Malian Infants
The purpose of this study is to assess the safety, tolerability, and pharmacokinetics of L9LS in infants in Mali and to evaluate the impact of L9LS on subsequent R21/Matrix-MTM vaccine immunogenicity.
- Trial name
- NCT06461026
- Testing
- L9LS, R21/Matrix-MTM
- Where
- 3 sites in Mali
- Volunteers
- 327 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Preclinical Alzheimer's Disease, Alzheimer Disease
Alzheimer's Tau Platform: Master Protocol
The goal of the Alzheimer's Tau Platform (ATP) is to evaluate the safety and effectiveness of tau-directed therapies, alone or in combination with the anti-amyloid monoclonal antibody, donanemab, in adults aged 50-80 with late…
- Conditions
- Preclinical Alzheimer's Disease, Alzheimer Disease, Prodromal Alzheimer's Disease
- Trial name
- ATP (NCT06957418)
- Testing
- AADvac1, Tau2
- Where
- 7 sites in United States
- Volunteers
- 900 people
- Sponsor
- Paul S. Aisen
RSV Immunization
Artificial Intelligence-assisted Primary Care for RSV Prevention (AIPC-RSV) in China
The goal of this clinical trial is to evaluate whether an AI-assisted primary care intervention for parents can increase RSV monoclonal antibody (mAb) uptake among infants, and to assess the cost-effectiveness and potential for…
- Trial name
- NCT07856290
- Testing
- RSV AI-assisted primary care intervention
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- Fudan University
Advanced Tumors
Phase I Clinical Trial of CDP1 in Patients With Advanced Solid Tumors
The main purpose of this study was to evaluate the safety and tolerability of CDP1 in patients with advanced solid tumor, to explore dose limited toxicity (DLT), and to determine the recommended dose (RP2D) for phase II clinical…
- Trial name
- NCT04151810
- Testing
- CDP1, TIP chemotherapy
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Dragonboat Biopharmaceutical Company Limited
Asthma
A Phase 2a Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Adults With Asthma
The primary objective of this study is to evaluate the safety and tolerability of escalating multiple subcutaneous (SC) doses of MEDI-563 in adult subjects with asthma.
- Trial name
- NCT00783289
- Testing
- Benralizumab 25 mg, Benralizumab 100 mg, Benralizumab 200 mg
- Where
- 6 sites in United States
- Volunteers
- 35 people
- Sponsor
- MedImmune LLC
Breast Cancer With Low Expression of HER2
ARX788 in Breast Cancer With Low Expression of HER2
A Phase 2 Study of ARX788 in unresectable and/or metastatic breast cancer with low expression of HER2.
- Trial name
- NCT05018676
- Testing
- ARX788
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Fudan University
Metastatic Colorectal Cancer (CRC)
Impact of Fusobacterium Nucleatum on Response to Anti-EGFR Therapy in Metastatic Colorectal Cancer
This retrospective observational cohort study investigates the association between the intratumoral burden of the bacterium Fusobacterium nucleatum (Fn) and the efficacy of anti-EGFR targeted therapies (cetuximab or panitumumab)…
- Trial name
- NCT07619859
- Where
- Brazil
- Volunteers
- 500 people
- Sponsor
- Barretos Cancer Hospital
Healthy
A First-in-human Study of a Novel Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody
The goal of this clinical trial is to study the tolerability, safety, pharmacokinetics and immunogenicity of investigational drug in healthy subjects.
- Trial name
- NCT06021574
- Testing
- VDJ001
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- The Affiliated Hospital of Qingdao University
mCRPC
Safety and Efficacy Evaluation of Anti IGF-1R Monoclonal Antibody Combined With Anti-PD-1 Monoclonal Antibody in Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
This trial is designed to evaluate the safety and efficacy of anti-IGF-1R mAb in combination with anti-PD-1 mAb in patients with mCRPC.
- Trial name
- NCT06866548
- Testing
- anti-IGF-1R mAb (Teprotumumab/IBI311) + anti-PD-1 mAb (Tislelizumab)
- Where
- China
- Volunteers
- 7 people
- Sponsor
- Shanghai Changzheng Hospital
Crohn Disease
Efficacy, Safety and Pharmacokinetics of BI 655066/ABBV-066 (Risankizumab) in Patients With Active, Moderate-to-severe Crohn's Disease.
This study is a proof of concept, multi-center, randomized, double-blind, placebo-controlled, parallel-group phase 2 dose-ranging study of BI 655066/ABBV-066 (risankizumab), an IL-23 p19 antagonist monoclonal antibody, in…
- Trial name
- NCT02031276
- Testing
- risankizumab IV, risankizumab SC
- Volunteers
- 121 people
- Sponsor
- AbbVie
Advanced Solid Tumors or Lymphoma
Safety, Tolerability, Pharmacokinetics and Efficacy of SCT-I10A in Patients With Advanced Solid Tumors or Lymphoma
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of recombinant humanized anti- PD-1 monoclonal antibody（SCT-I10A）in patients with advanced solid tumors or lymphoma…
- Trial name
- NCT03821363
- Testing
- SCT-I10A
- Where
- China
- Volunteers
- 206 people
- Sponsor
- Sinocelltech Ltd.
Acute Respiratory Distress Syndrome, Adult Respiratory Distress Syndrome
Anti-CD14 Treatment With IC14 in Hospitalized ARDS Patients
Hospitalized patients with ARDS will be randomized to intravenous treatment with a monoclonal antibody against CD14, called IC14, or placebo. They will be followed for 28 days.
- Conditions
- Acute Respiratory Distress Syndrome, Adult Respiratory Distress Syndrome, Acute Lung Injury, Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)
- Trial name
- NCT06513949
- Testing
- Atibuclimab
- Where
- 2 sites in United States
- Volunteers
- 56 people
- Sponsor
- Implicit Bioscience
Crohn Disease
A Study of Ustekinumab (STELARA) in Chinese Participants With Moderately to Severely Active Crohn's Disease
The purpose of this study is to evaluate the clinical and endoscopic efficacy and safety of ustekinumab in Chinese participants with moderately to severely active Crohn's disease.
- Trial name
- NCT05029921
- Testing
- Ustekinumab
- Where
- 29 sites in China
- Volunteers
- 182 people
- Sponsor
- Janssen Research & Development, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.